Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation
Brian O’Sullivan(University of Toronto), Wei Xu(University Health Network), Andrew Hope(University of Toronto), Ilan Weinreb(University Health Network), Jolie Ringash(University Health Network), John Waldron(Princess Margaret Cancer Centre), Laura A. Dawson(Princess Margaret Cancer Centre), Andrew Bayley(University Health Network), Jonathan C. Irish(Princess Margaret Cancer Centre), Bayardo Perez‐Ordoñez(University Health Network), Eric X. Chen(Princess Margaret Cancer Centre), B.C. John Cho(Princess Margaret Cancer Centre), Shao Hui Huang(University of Toronto), Helen Zhao(Princess Margaret Cancer Centre), John Kim(University of Michigan), Bernard Cummings(University of Toronto), Christine Massey(University of Vermont), Ralph Gilbert(Princess Margaret Cancer Centre), Lillian L. Siu(University Health Network), Angela Bik‐Yu Hui(Stanford University), Fei‐Fei Liu(Jiangsu Hengrui Medicine (China))
Cited by 184
Related Papers
Dose Escalation Methods in Phase I Cancer Clinical Trials
|JNCI Journal of the National Cancer Institute|2009|856
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
|Journal of Clinical Oncology|2013|841
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
|Journal of Clinical Oncology|2010|806
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770
Prognostic Significance of p16 <sup>INK4A</sup> and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial
|Journal of Clinical Oncology|2010|741